STOCK TITAN

Enlivex Therapeutics Ltd - ENLV STOCK NEWS

Welcome to our dedicated news page for Enlivex Therapeutics (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enlivex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enlivex Therapeutics's position in the market.

Rhea-AI Summary
Enlivex Therapeutics has announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. The amended protocol allows a higher SOFA score inclusion range, allowing the recruitment of patients with higher levels of sepsis severity. The protocol also provides for two cohorts (treatment and placebo) instead of four, streamlining the trial. The company expects the top-line data readout from the Phase II trial to be in Q1 2024, consistent with their previously announced timeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
earnings
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present a corporate update at the 2023 Jefferies Healthcare Conference on June 9, 2022, at 11:30 AM Eastern Time. The webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.35%
Tags
earnings
Enlivex Therapeutics Ltd

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

71.79M
14.51M
11.81%
8.93%
1.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
14 Einstein St

About ENLV

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re